Key Drivers
- Strong Returns
- Cash Generation
- High Leverage
AIAI Summary
HAE is now a proof-of-execution story rather than a simple beat-and-raise name: the stock has upside if recent product/regulatory wins from plasma and VASCADE translate into broader multi-quarter growth, but guided revenue decline and gross-margin pressure mean the valuation rebound is only credible if management proves sustainable operating momentum soon.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Returns
- •Cash Generation
- •High Leverage
H&E Equipment Services is profitable and cash-generative with improving margins, but elevated leverage and heavy intangible assets limit the investment case despite a valuation that is not cheap.
Price Behavior
Key Price Behavior Insights:
- •Oversold Bounce
- •Resistance Cap
- •Support Fragile
HAE remains in a corrective phase over the last month, with a sharp oversold bounce offset by weak follow-through and upside still capped below $57.1-$57.3 and $59-$60.
Sharp rebound from $52.24 to $57.12 after a steep selloff signals short-term oversold conditions
Sentiment & News
Key News Insights:
- •Earnings beat
- •Margin pressure
- •Product momentum
Haemonetics delivered a solid Q4 FY26 beat with moderate sales growth, but margin pressure and a cautious FY27 outlook kept investor reaction mixed.
The results and product strength are supportive, but margin declines and forward guidance suggest limited near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings